New combo therapy targets rare spine cancer in early trial
NCT ID NCT02989636
First seen Jan 08, 2026 · Last updated May 24, 2026 · Updated 25 times
Summary
This early-stage study tests the safety of combining an immunotherapy drug (nivolumab) with or without precise radiation (stereotactic radiosurgery) in 21 people with chordoma that has returned or spread. The goal is to see if this combination is safe and tolerable. Participants must have confirmed chordoma and evidence of disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHORDOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.